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Autosomal-recessive early-onset parkinsonism is clinically and genetically heterogeneous. The genetic causes of approximately 50% of
autosomal-recessive early-onset forms of Parkinson disease (PD) remain to be elucidated. Homozygozity mapping and exome
sequencing in 62 isolated individuals with early-onset parkinsonism and confirmed consanguinity followed by data mining in the
exomes of 1,348 PD-affected individuals identified, in three isolated subjects, homozygous or compound heterozygous truncating
mutations in vacuolar protein sorting 13C (VPS13C). VPS13C mutations are associated with a distinct form of early-onset parkinsonism
characterized by rapid and severe disease progression and early cognitive decline; the pathological features were striking and reminiscent
of diffuse Lewy body disease. In cell models, VPS13C partly localized to the outer membrane of mitochondria. Silencing of VPS13C was
associated with lower mitochondrial membrane potential, mitochondrial fragmentation, increased respiration rates, exacerbated
PINK1/Parkin-dependent mitophagy, and transcriptional upregulation of PARK2 in response to mitochondrial damage. This work sug-
gests that loss of function of VPS13C is a cause of autosomal-recessive early-onset parkinsonism with a distinctive phenotype of rapid
and severe progression.Introduction
Parkinson disease (PD [MIM: 168600]) is a motor syn-
drome with variable combinations of akinesia, rigidity,
and rest tremor responding to levodopa. It is caused by
degeneration of the dopaminergic neurons in the sub-
stantia nigra pars compacta and is associated with Lewy
bodies, intraneuronal inclusions enriched in a-synuclein.
In recent years, our understanding of the pathophysiolog-
ical mechanisms underlying molecular defects in familial
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forms of PD (SNCA [MIM: 163890], LRRK2 [MIM:
609007], and VPS35 [MIM: 601501]) and eight genes
(PARK2 [MIM: 602544], PINK1 [MIM: 608309], DJ-1
[MIM: 602533], ATP13A2 [MIM: 610513], FBXO7 [MIM:
605648], PLA2G6 [MIM: 603604], SYNJ1 [MIM: 604297],
and DNAJC6 [MIM: 608375]) with early-onset (EO) auto-
somal-recessive (AR) forms.1 EO AR parkinsonism is clini-
cally and genetically heterogeneous: mutations in PARK2,
PINK1, and DJ-1 cause phenotypes similar to idiopathic
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therapy. Other EO AR PD-associated genes cause more
severe disease, a poor response to levodopa, and additional
clinical signs, such as dystonia and cognitive impairment.1
Mutations in PARK2 and PINK1 are the most common
cause of EO AR PD, accounting for ~50% and 4% of familial
cases in Europe, respectively.2,3 A significant proportion of
cases remain genetically unexplained.
EO AR PD is linked to mitochondrial dysfunction.
The mitochondrial kinase PINK1 and the E3 ubiquitin-
protein ligase Parkin cooperate in mitochondrial quality
control.4 They promote the removal of dysfunctional
mitochondria in a process termed mitophagy that might
also involve FBXO7.4,5 In addition, they play a role in a ve-
sicular trafficking pathway targeting damaged mitochon-
drial components to the lysosome.6 To identify additional
PD-associated genes involved in AR EO parkinsonism, we
performed homozygosity mapping and exome sequencing
in consanguineous PD families and isolated individuals
and used data mining in the exomes of 1,348 unrelated
PD-affected individuals. Five truncating mutations in
vacuolar protein sorting 13C (VPS13C [MIM: 608879]) were
identified in three unrelated PD-affected isolated indi-
viduals. We provide evidence that depletion of VPS13C ex-
acerbates mitochondrial vulnerability to stress.Subjects and Methods
Participants
Gene Discovery Cohort
We selected nine PD-affected families (with two or more affected
siblings) and 43 unrelated isolated individuals according to the
following criteria: (1) diagnosed by neurologists according to the
UK Parkinson’s Disease Society Brain Bank (PDSBB) clinical diag-
nostic criteria7 and onset%55 years in at least one affected family
member; (2) with no mutations in known PD-associated genes;
and (3) with confirmed consanguinity (inbreeding coefficient
Fs0 computed with the FEstim program8). Sixteen families or iso-
lated subjects were European, 16 North African, 19 Turkish, and 1
Lebanese. A total of 66 PD-affected individuals (23 familymembers
and 43 isolated subjects) and 39 unaffected relatives were included
for the genome-wide screen study. 62 affected and10unaffected in-
dividualswere subsequently selected for whole-exome sequencing.
Validation Cohort
Exome data were obtained from a series of 1,348 additional PD-
affected individuals (99% unrelated, 99% of European ancestry,
60% males, mean age at onset 41.7 5 11.0 years), including 249
French PD-affected probands (57%males, age at onset% 40 years,
50 individuals with atypical forms of parkinsonism) recruited by
the French network for the study of PD genetics (PDG) and 530
matched control subjects (95% of European ancestry, 65% males,
mean age at examination: 45.1 5 10.7 years) from the Interna-
tional Parkinson Disease Genomics Consortium (IPDGC).
100 Turkish control subjects without family history of PD (43%
males; mean age at examination, 60.4 5 13.9 years) served to
check for the absence of the identified variant in family A, which
originated from Turkey.
A flow diagram detailing the selection criteria of PD-affected
individuals and control subjects and the different experimental
steps of the study is provided (Figure S1).The AmeStudy Approval
Informed consent was obtained from all participants, and the ge-
netic studies were approved by local ethics committees (INSERM,
CCPPRB du Groupe Hospitalier Pitie´-Salpeˆtrie`re, Paris, France).Neuropathological Assessment
The autopsy of the affected individual II-1 in family B (Figure 1)
was performed approximately 36 hr post mortem. Brain tissues
were fixed for 6 weeks in 10% buffered formalin, extensively
sampled, and processed as previously described.9 Immunohis-
tochemistry was performed by a Ventana Benchmark automate.
We used hematoxylin-eosin staining for histopathology. For
immunochemistry, the antibodies used were: anti-Tau (in-house
AD2,10 1 ng/mL), anti-b-amyloid (4G8, 1:1,000, Sigma), anti-
a-synuclein (LB509, 1:500, Abcam), anti-ubiquitin (1:1,000,
Dako), anti-TDP-43 (1:500, Protein Tech), and anti-glial fibrillary
acid protein (GFAP, 1:20,000, Dako). The degree of neuronal
loss and the frequency of a-synuclein-immunoreactive and
other inclusions were determined semiquantitatively by visual
inspection, in comparison to brains of three age-matched con-
trols (two males and one female) from the Lille Neurobank
collection.Molecular Studies
Whole-Genome Homozygosity Linkage Mapping
Genome-wide screens were performed on all available affected
(n ¼ 66) and unaffected (n ¼ 39) individuals from the gene
discovery cohort using the Illumina HumanCytoSNP-12 v2.1
DNA Analysis BeadChip microarrays that contain ~300,000
SNPs and ~1,300 markers of common copy-number variations
(CNVs). Homozygosity tracks (>2 Mb) were visualized with
the Homozygosity Detector module and CNV with the Illu-
mina cnvPartition module. The inbreeding coefficients F were
computed with the FEstim program.8 Samples from individuals
with confirmed consanguinity (Fs0) were subjected to exome
sequencing.
Whole-Exome Sequencing
Exons from 62 affected (19 relatives and 43 isolated individuals)
and 10 unaffected familymembers from the gene discovery cohort
and all the 1,348 affected and 530 control individuals from the
validation cohort were captured using different exome enrich-
ment kits from fragmented genomic DNA and sequenced as indi-
cated in Table S1. 10-fold mean sequencing depth was achieved in
96.4% and 88.8% of baited regions in PD-affected individuals and
control subjects, respectively, and 30-fold mean sequencing depth
was achieved across ~75% of targeted regions.
Human reference sequence UCSC hg19 was used for sequence
alignment and variant calling with the Burrows-Wheeler
Aligner11 and the Genome Analysis Toolkit.12 PCR duplicates
were removed prior to variant calling using Picard software. Vari-
ants were annotated with ANNOVAR software13 (exomes from
validation cohort) or SnpEff and SnpSift programs (exomes from
gene discovery cohort). Data were analyzed with Ingenuity
Variant Analysis (IVA) TM software from Ingenuity System. Effects
on mRNA splicing by putative splice variants (55 base pairs
around splice junctions according to IVA threshold) were analyzed
with Splice Site Finder, MaxEntScan, NNsplice, Genesplicer, and
Human Splicing Finder,14–16 all included in Alamut v.3 software.
The humanVPS13C protein and its closest homologs were aligned
with Alamut v.3 software, computed by Ensembl, and alignedwith
MUSCLE.rican Journal of Human Genetics 98, 500–513, March 3, 2016 501
Figure 1. Identification of VPS13C Mutations
(A) Pedigrees of families with VPS13Cmutations. Black symbols represent individuals with PD, open symbols, those unaffected. Arrows
point to probands who underwent whole-exome sequencing. Abbreviations are as follows: AE, age at examination; AD, age at death;
AO, age at onset.
(B) Schematic representation of VPS13C and its variations. VPS13C spans 208 kb and contains 86 exons encoding a 3,753-amino
acid protein with a chorein domain at its N terminus, a DUF1162 domain of unknown function, and a putative autophagy-related
domain. The five variations found in the three probands are indicated. Numbers above the gene identify the exons containing
VPS13C variations. Alternative splicing a and b represent skipping of exons 6þ7 and of exon 82, respectively. Transcripts 1A, GenBank:
NM_017684.4: splicing a þ b; 2A, GenBank: NM_020821.2: splicing b; 1B, GenBank: NM_018080.3: ends at exon 82; 2B, GenBank:
NM_001018088.2: splicing a and ends at exon 82.An in-house pipeline crossed the output data from IVA and
Homozygosity Mapping to filter and identify the variants of
interest (Figure S2). These variants were visualized with the Broad
Institute Integrative Genomics Viewer (IGV) and verified by bidi-
rectional Sanger sequencing using primers designed with Primer3
(Table S2) on an ABI 3730 automated sequencer (Life Technolo-
gies). Sanger sequencing confirmed the absence of mutations in
origin-matched controls and determined the genetic status of
unaffected relatives. Mutation nomenclature follows Human
Genome Variation Society (HGVS) recommendations: the longest
VPS13C transcript 2A cDNA nucleotides (‘‘c.’’) are numbered
from the adenine of the first ATG translation initiation codon as
nucleotide þ1 (reference sequence GenBank: NM_020821.2).502 The American Journal of Human Genetics 98, 500–513, March 3Splicing Defect Analysis by RT-PCR
Keratinocytes from affected individual V-2 in family A or
peripheral blood lymphocytes from affected individual II-1 in
family C (Figure 1) were used for splicing defects analyses.
Hair follicles were plucked under sterile conditions and cultured
in flasks coated with MG (1:10, Corning). Keratinocytes were
grown on 20 mg/mL collagen IV (Sigma-Aldrich)-coated dishes
containing EpiLife medium with the HKGS supplement (Life
Technologies). Total RNA extraction was carried out with
the RNeasy Kit (QIAGEN), according to the manufacture’s
manual. RNA (250 ng) was reverse transcribed into cDNA using
iScript reverse transcription supermix (Bio-Rad). Primers are
listed in Table S2. RT-PCR products were Sanger sequenced, 2016
directly or after sub-cloning into the pJET1.2/blunt vector
(Thermo Scientific).Studies in Mammalian Cells
Mammalian Expression Vectors, siRNAs, Cell Culture, and Transfection
COS-7 and HEK293T cells were grown in Dulbecco’s Modified
Eagle Medium þ Glutamax (Life Technologies) supplemented
with 10% goat serum (Life Technologies) and 1% penicillin-strep-
tomycin (Life Technologies). Cells were plated, at 80% conflu-
ence, on glass coverslips (Thermo Scientific) in 24-well cell plates
for immunofluorescence, 6-well plates for qPCR, 10-cm Petri
dishes for subcellular fractionation by differential centrifugation
and for the mitochondrion isolation kit, or 75-cm2 flasks for
continuous sucrose gradient and Percoll gradient purification.
Cells were co-transfected with siRNAs (15 to 30 nM) and expres-
sion vectors using Lipofectamine 2000 (Life Technologies), in an
antibiotic-free medium, according to the manufacturer’s instruc-
tions. The siRNA used were: Hs_VPS13C_5 and Hs_VPS13C_6
(siVPS13C, QIAGEN); PINK1 stealth siRNAs (siPINK1, Invitrogen);
and AllStars negative control siRNA (siControl, QIAGEN).
Their efficacy was controlled by quantitative real-time RT-PCR
(Figure 5F). The expression vectors were: pcDNA3-HA-PARK2,
pcDNA3-HA-PINK1, pcDNA3-HA,17 and pEGFP-C1 (Life Technol-
ogies). Where indicated, the cells were incubated with 10 mM
CCCP (Sigma).
Subcellular Fractionation, Trypsin Digestion Assay, and Western Blot
Analyses
For sucrose density gradient, confluent HEK293T cells from five
75-cm2 flasks were harvested and disruptedwith a Dounce homog-
enizer (80 manual strokes) in 10 mM Tris-HCl buffer (pH 7.6)
containing 10% w/v sucrose, 10 mM ethylenediaminetetraacetic
acid (EDTA), 0.5 mM dithiothreitol (DTT), supplemented with
protease and phosphatase inhibitors (0.2 mM sodium orthovana-
date, 4 mg/mL sodium fluoride, 5.4 mg/mL b-glycerophosphate,
and Complete cocktail 1X – 11836145001, Roche). After three
centrifugations at 600 3 g for 5 min to remove cell debris, the
cell lysate was layered on a 20%–60% linear sucrose gradient in
Tris-HCl (pH 7.6) containing 10 mM EDTA, as previously
described.18 After 18 hr of centrifugation at 100,000 3 g, succes-
sive 0.8 mL fractions were collected. Proteins were precipitated
on ice with 10% trichloroacetic acid, pelleted by centrifugation
at 13,000 3 g for 45 min, and resuspended in 100 mL of loading
buffer (Tris 60 mM [pH 6.8], SDS 4%, b-mercaptoethanol 5%,
glycerol, and bromophenol blue).
Total protein fractions were obtained from cells lysed in 210mM
mannitol, 70 mM sucrose, 5 mM Tris (pH 7.4), 0.2 mM EGTA,
0.1 mM EDTA, 0.5 mM DTT, 0.1% BSA, and protease and phos-
phatase inhibitors after centrifugation at 600 3 g for 5 min
at room temperature. Mitochondrion-enriched fractions were
obtained by differential centrifugation (HEK293T) or magnetic
isolation (COS-7) and digested with trypsin (Sigma), as previously
described.17,19
For isolation of pure mitochondria, cells were lysed in 250 mM
mannitol, 5 mM HEPES (pH 7.4), 5 mM EGTA with protease, and
phosphatase inhibitors and the crude mitochondrial fraction was
layered on top of a 30% Percoll gradient, as previously described.20
Protein concentrations were determined with Bio-Rad protein
assays (Bio-Rad, 500-0006), based on the Bradford method. Sam-
ples were boiled in protein sample buffer, resolved by SDS-PAGE,
transferred onto a nitrocellulose membrane (Protran, Whatman),
and analyzed by Western blotting with selected primary andThe Amesecondary antibodies (Table S3). Membranes were incubated
with enhanced chemiluminescence substrate (Pierce); chemi-
luminescent and fluorescent signals were revealed on film (ECL,
Amersham Hyperfilm) or captured with Odyssey Imaging (Li-
COR) systems and quantified with ImageJ software (NIH). Total
or cytoplasmic fractions were normalized to a-tubulin, mitochon-
drial fractions to PMPCB. Three to six independent fractionation
experiments were quantified.
Analysis of Mitochondrial Respiration
Cellular oxygen consumption was measured via high-resolu-
tion respirometry (OROBOROS Oxygraph-2k) in a temperature-
regulated chamber at 37C. Oxygen consumption was measured
in intact COS-7 cells at a density of 2.5 3 106 cells in 2 mL
of respiration assay medium (13 DMEM, GlutaMAX, GIBCO)
containing 4.5 g/L D-glucose and 4 mM L-glutamine, by sequen-
tial additions of 1 mg/mL oligomycin, 2.5 mM CCCP, and 5 mM
rotenone/10 mM antimycin A. We determined the following
mitochondrial parameters: basal oxygen consumption (¼ basal
cellular respiration  non-mitochondrial respiration), proton
leak (¼ oligomycin-inhibited respiration  non-mitochondrial
respiration), maximal respiratory capacity (¼ maximal un-
coupled respiration  non-mitochondrial respiration), reserve
respiratory capacity (¼ maximal uncoupled respiration  basal
respiration), and non-mitochondrial respiration (rotenone/anti-
mycin A-inhibited respiration). Cells were then lysed to quantify
the protein content using the Bradford reagent, which was used
to normalize the oxygen consumption data. The results were
expressed in pmol of O2/s/mg of total protein.
Immunostaining, DJmt, Respiration, Mitochondrial Morphology, and
Parkin-Dependent Mitophagy
Immunocytochemical stainings were performed as described
previously with the antibodies and dilution conditions indicated
in Table S3. Changes in DJmt were evaluated with the poten-
tiometric dye tetramethylrhodamine methyl ester (TMRM) as
described.19 Mitochondrial morphology was analyzed on
COS-7 cells immunostained for the Beta subunit of the mito-
chondrial processing peptidase (PMPCB) using an image-process-
ing algorithm and two descriptive parameters to assess mito-
chondrial length and branching: aspect ratio, calculated as the
ratio between major and minor axes of each mitochondrial ob-
ject, representing its length; and form factor, calculated as perim-
eter2/(4p 3 area), representing a combined evaluation of the
length and degree of branching of the mitochondrial
network.21,22 For Parkin-dependent mitophagy, cells were immu-
nostained for PMPCB or the outer mitochondrial membrane
protein TOMM20 and quantified as described.17 Images were ac-
quired with an Olympus FV-1000 confocal microscope (360 oil
immersion objective, NA 1.35) and analyzed with ImageJ anal-
ysis software (NIH).
Quantitative Real-Time RT-PCR
To demonstrate the efficiency of the siRNA-mediated silencing of
endogenous VPS13C in HEK293T cells, total RNA was isolated
from cells transfected with control or VPS13C or PINK1 siRNA
using the RNeasy plus Mini Kit (QIAGEN) and QIAshredder
(QIAGEN). RNA from each sample (500 ng) was reverse transcribed
into cDNA using iScript reverse transcription supermix (Bio-Rad).
Real-time PCR was performed with the LightCycler 480 System
(Roche Applied Science) and SsoAdvanced Universal SYBR Green
Supermix (Bio-Rad). Results were analyzed with LightCycler 480
sw 1.5 quantification Software (Roche Applied Science). Beta-actin
(ACTB) was used as the reference gene for normalization. Primers
are listed in Table S2.rican Journal of Human Genetics 98, 500–513, March 3, 2016 503
Statistical Analysis
Statistical significance was established at p < 0.05 and determined
with an unpaired t test in Figures 4A (Aspect Ratio) and S6A;
matched t test in Figures 4C, 5B, and 5D; Mann-Whitney-
Wilcoxon test in Figure 4A (Form Factor); one-way ANOVA in Fig-
ures 6 and S5; or two-way ANOVA in Figures 4B, 5E, and 5F.Results
Truncating Mutations in VPS13C Cause AR
Parkinsonism
Genome-wide screens in an initial series of 66 affected and
39 unaffected subjects using DNA microarrays identified a
mean of 16.3 regions of homozygosity R 2 Mb on the 22
autosomes of each consanguineous individual (gene dis-
covery cohort). No rare deleterious large genomic rear-
rangements were detected. Exomes were subsequently
sequenced in the 62 affected individuals with confirmed
consanguinity (inbreeding coefficient Fs0) and 10 unaf-
fected family members to identify homozygous variants
which: (1) in priority, would disrupt the protein function
(frameshifts, stop codons, or splicing variants); (2) were
rare (minor allele frequency [MAF] < 1%) in dbSNP137,
the National Heart Lung and Blood Institute (NHBLI),
Exome Sequencing Project (ESP) database, and the 1000
Genomes Project; (3) were shared by affected siblings
when available; (4) were heterozygous in parents and/or
heterozygous or wild-type in unaffected siblings when
available; (5) fell within homozygous intervals; and (6)
were absent in the homozygous state from DNA of 530
controls. We identified rare or undescribed homozygous
truncating variants within 32 genes, each found in a single
affected individual with consanguinity that fulfilled all
these prioritization criteria (Table S4). We screened these
candidate genes for additional homozygous or compound
heterozygous mutations in a validation cohort. VPS13C
(also known as KIAA1421; GenBank: NM_020821.2) on
chr15q22 was mutated in a consanguineous Turkish
PD-affected individual (V-2 in family A) from the gene dis-
covery cohort and in two additional French PD-affected
isolated individuals (II.1 in family B and II.1 in family C)
from the validation cohort (Figure 1A). In addition, we
identified a total of 80 rare (MAF < 1% in public databases)
single heterozygous mostly nonsynonymous variants in
VPS13C from the validation cohort, including 14 present
in at least one of the 530 European control subjects (Table
S5). No additional homozygous or compound heterozy-
gous variants were found in the 31 other candidate genes.
The affected individual V-2 in family A harbored a
homozygous splice-site mutation c.8445þ2T>G, intron
61 in VPS13C confirmed by Sanger sequencing; eight
unaffected relatives, including the mother, had hetero-
zygous c.8445þ2T>G mutations or wild-type sequences
(Figures 1A and S3A). Affected individuals in families
B and C were compound heterozygotes (Figures 1A,
S3B, and S3C): the affected individual II-1 in family
B with c.[806_807insCAGA];[ 9568G>T], p.[Arg269Serfs*504 The American Journal of Human Genetics 98, 500–513, March 314];[Glu3190*] variants; the affected individual II-1 in
family C with c.[4165G>C];[4777delC], p.[Gly1389Arg];
[Gln1593Lysfs*7] variants. Direct sequencing of VPS13C
in the three unaffected siblings (II-2, II-3, and II-4) in fam-
ily B and the unaffected mother (I-1) in family C showed
that they all carried heterozygous mutations or wild-type
alleles (Figures 1A and S3), indicating that all variations
were located on different alleles. The five VPS13C variants
were absent from dbSNP137, 1000 Genomes Project, EVS
(Table S6A), Exome Aggregation Consortium (ExAC) data-
bases (Table S6B), and our European control exomes,
except for the missense p.Gly1389Arg variant found on
one control chromosome. In addition, the c.8445þ2T>G
mutation was absent from 200 Turkish control chromo-
somes. No disruptive bi-allelic variants were found in our
530 control subjects; one disruptive homozygous variant
(rs199602573) was found in the EVS database and ExAC
populations (1/6,246 and 2/61,547, respectively), indi-
cating that VPS13C homozygous disruptive variants are
extremely rare in non-PD-affected populations (Tables S6
and S7).
The c.4165G>C and c.8445þ2T>G mutations were
predicted in silico to modify donor splice sites, one base
upstream and two bases downstream, respectively, of splice
junctions (Figure S4A). Reverse-transcription PCR analysis
of potential splicing defects confirmed the predictions
(Figure S4B). RNA from the homozygous individual of
family A showed at least three shorter transcripts, lacking
up to 231 nucleotides at the end of the exon 61. In the sub-
ject with the heterozygous variant, shorter transcripts were
barely visible, probably due to a high instability of these
aberrant RNAs. In family C, the longer transcript was
found in the subject with the heterozygous variant, con-
taining 14 additional nucleotides from intron 37.
VPS13C contains 86 exons spanning a 208-kb genomic
region and has twomain transcript variants, 1A (GenBank:
NM_017684.4) and 2A (GenBank: NM_020821.2) (Fig-
ure 1B). Although the transcript 1A, lacking exons 6 and 7
and encoding a 3,710-amino acid protein, is expressed in
most tissues, including brain and peripheral blood cells,
the longest transcript 2A encodes a brain-specific 3,753-
amino acid protein.23 Two additional isoforms with un-
characterized expression pattern are reported in Ensembl
(GenBank: NM_018080.3 and NM_001018088.2) and lack
the last four exons. All the isoforms contain the splice site
variants found in families A and C. VPS13C contains a
chorein domain at its N terminus, a DUF1162 domain of
unknown function, and a putative autophagy-related
domain (Figure 1B). Except for the c.8445þ2T>G variant,
which is located in the DUF1162 domain, none of the
variants were found in the predicted domains.
Clinical and Pathological Characteristics of Affected
Individuals Harboring VPS13C Mutations
The three affected individuals harboring VPS13C muta-
tions had early disease onset (25 to <46 years) and typical
parkinsonism (akineto-rigid syndrome, rest tremor, good, 2016
Table 1. Clinical Characteristics of Affected Individuals Harboring VPS13C Mutations
V-2 from Family A II-1 from Family B II-1 from Family C
Origin Turkish French French
Consanguinity yes no no
Gender female male female
Age at onset (years) <46 33 25
Symptoms at onset depression; asymetric akineto rigid
syndrome; no dystonia
asymetric akineto rigid syndrome
and rest tremor; limb dystonia
asymetric akineto rigid syndrome;
limb dystonia
Response to levodopa yes, partial yes, at early stage yes, at early stage (evaluated at 75%
initially)
Complications with treatment no motor fluctuation nor dyskinesia fluctuation and dyskinesia, ICD,
somnolence
no motor fluctuation nor dyskinesia
Evolution severe with early cognitive
decline with spatial disorientation
(MMSE 21), slurred speech and
hallucinations at the age of 51; axial
symptoms (postural instability, FOG,
and falls) and dysautonomia with
urinary incontinence at the age
of 54; bedridden, unable to speak,
apathetic, confused, cachexic with
dysphagia at the age of 58
severe with early cognitive decline
(MMSE 18 at the age of 40); axial
symptoms (FOG at the age of 35,
falls at the age of 39); dysautonomia
(at the age of 35); bedridden at the
age of 43, death at the age of 49 of
aspiration pneumonia
severe with early cognitive decline,
slurred speech before the age of 39;
severe axial symptoms at early
stage; bedridden at the age of 31;
gastrostomia at the age of 37.
Subject’s father died at 52 of a
pancreatic cancer
Atypical symptoms associated brisk tendon reflexes on the lower
limbs but no pyramidal syndrome
motor neuron signs with pyramidal
syndrome and limb atrophy at late
stage
motor neuron signs with spastic
tetraplegia
Cerebral MRI asymmetric atrophy in frontal,
parietal, and temporal areas at the
expense of the left side
normal (performed at early stage) normal (performed at early stage)
Abbreviations are as follows: ICD, impulse control disorder; MMSE, mini-mental state examination; FOG, freezing of gait.levodopa response). Disease progression, however, was
particularly severe, with early cognitive decline, loss of
response to treatment, axial symptoms, and dysautono-
mia. Affected subjects were bedridden within 15 years of
clinical onset. Pyramidal signs and motor deficits were
observed in two affected individuals. Brain MRI was
normal early in the disease, and then bilateral atrophy
was observed in the frontal, parietal, and temporal lobes
(Table 1). Post-mortem examination of the brain of
the affected individual II-1 in family B, who died at age
49 of aspiration pneumonia, showed mild frontal
atrophy, including the primary motor area (Figures 2A–
2C). The pathology resembled diffuse Lewy body disease.
Alpha-synuclein and ubiquitin positive-Lewy bodies were
observed in the brainstem, limbic system, hippocampus,
and all cortical associative areas, including the parieto-
occipital region (Figures 2D–2F, Table S8). Tau-immunore-
active neurofibrillary tangles and neurites were seen in
the brainstem, hippocampus, and primary motor cortex
(Figure 2G, Table S8). There were no glial-, a-synuclein-,
Ab-, or TDP-43-immunoreactive inclusions.
Loss of VPS13C Function Affects Mitochondrial
Morphology, Transmembrane Potential, and
Respiration
To investigate the function of VPS13C, we explored its
subcellular distribution in human HEK293T by sucroseThe Amegradient fractionation (Figure 3A). VPS13C was enriched
in the low-density fractions 1 and 2 containing the early
endosomal marker EEA1 and most of the cytosolic protein
Parkin. VPS13C was also found in higher-density fractions
containing membrane and soluble markers of the Golgi
apparatus (GOLGA2), the ER (Calnexin, BiP), and mito-
chondria (TOMM70, PMPCB, PINK1). Here, it was most
abundant in fractions 8–10, containing the greatest pro-
portion of TOMM70 and PMPCB. The mitochondrial
localization of VPS13C was confirmed in mitochondrion-
enriched fractions and pure mitochondria from HEK293T
and COS-7 cells (Figures 3B and 3C). Limited trypsin
digestion of mitochondrion-enriched fractions caused
concomitant loss of VPS13C and the outer mitochondrial
membrane receptor TOMM70 under conditions preserving
the outer mitochondrial membrane channel TOMM40
and mitochondrial matrix enzyme PMPCB, indicating
that VPS13C is located on the mitochondrial surface
(Figure 3C).
We then investigated the impact of loss of VPS13C
function on mitochondrial morphology, transmembrane
potential, and respiration, reported to be affected in
models of PINK1 or PARK2 deficiency.24,25 The siRNA-
mediated silencing of VPS13C in COS-7 cells reduced
VPS13C mRNA levels to no more than 25% of the control
condition (Figure S6) and was associated with perinu-
clear redistribution of mitochondria and mitochondrialrican Journal of Human Genetics 98, 500–513, March 3, 2016 505
Figure 2. Neuropathology in the Proband of Family B with c.[806_807insCAGA];[9568G>T] VPS13C Mutations Shows Abundant
a-Synucleinopathy
(A–C) Macroscopic appearance of the left hemisphere (fixed): lateral view (A); medial view (B); coronal section at the level of the cerebral
peduncle (C).
(D and E) Lewy bodies in pigmented neurons in the substantia nigra (D, arrow, hematoxylin-eosin [HE] staining) and the parietal
neocortex (E, arrowhead, HE staining).
(F) Representative image of a-synuclein immunoreactivity in the frontal cortex showing abundant Lewy bodies and neurites.
(G) Tau-immunoreactive neurofibrillary tangles in the primary motor cortex.
Scale bars for microscopic images represent 50 mm.fragmentation, as confirmed by quantitative image analysis
(Figure 4A). Evaluation of the mitochondrial transmem-
brane potential (DJmt) with the potentiometric dye tetra-
methylrhodamine methyl ester (TMRM) revealed a sig-
nificant decrease in the mean fluorescence intensity of
mitochondria in cells depleted of VPS13C (Figure 4B). The
DJmtdecreasewas accompanied by an increase inmaximal
respiration rates and respiratory reserve, as assessed by high-
resolution respirometry in intact cells (Figure 4C). Similar
results were obtained in HEK293T cells (data not shown).Loss of VPS13C Function Exacerbates PINK1/Parkin-
Dependent Responses to Mitochondrial
Depolarization
We further investigated the relationship between VPS13C
and PINK1 and PARK2, both at the transcript and protein
levels, with respect to their well-characterized response
to mitochondrial damage. PINK1 accumulates on mito-
chondria and recruits Parkin to initiate mitophagy in
response to mitochondrial dysfunction.4 Mitochondrial
depolarization, triggered by the protonophore CCCP,
partially redistributed VPS13C from mitochondria to the
cytoplasm without significantly changing VPS13C tran-
script levels (Figures 5A, 5B, and 5F, left); under these condi-
tions, PINK1 accumulated on mitochondria, as expected.4
VPS13C silencing did not affect PINK1 levels under basal
conditions, but it exacerbated CCCP-induced mitochon-506 The American Journal of Human Genetics 98, 500–513, March 3drial accumulation of PINK1 without impacting PINK1
mRNA abundance (Figures 5C, 5D, and 5F, middle). More-
over,VPS13C silencing enhancedmitochondrial transloca-
tion of Parkin triggered byCCCP (Figures 5C and 5E). It also
upregulated Parkin protein abundance in the cytosol
without affecting PARK2 transcript levels at 3 hr of CCCP
treatment (Figures 5E and 5F, right). PARK2 expression
increases in response to mitochondrial damage caused by
mitochondrial toxins, including CCCP.26,27 Here, PARK2
transcript levels tended to be higher at 48 hr of CCCP treat-
ment (Figure 5F, right). This response was significantly
enhanced after silencing of VPS13C or PINK1, suggesting
greater mitochondrial damage. PINK1 silencing was also
associatedwith downregulation ofVPS13C transcript levels
under basal conditions (Figure 5F, left), an effect that was
reversed by PINK1 overproduction (Figure S5), indicating
the existence of multiple regulatory loops between
VPS13C, PARK2, and PINK1. Consistent with the above
described effects on PINK1 and Parkin, VPS13C silencing
exacerbated PINK1/Parkin-mediated mitophagy triggered
by CCCP in COS-7 cells, a model that we previously vali-
dated for the study of this process (Figures 6 and S6).17,19Discussion
This study establishes VPS13C mutations as a monogenic
cause of EO AR parkinsonism. Homozygous or compound, 2016
Figure 3. A Pool of VPS13C Is Located on
the Outer Mitochondrial Membrane
(A) Sucrose gradient fractionation illus-
trating the subcellular distribution of
endogenous VPS13C in HEK293T. Note
the enrichment of the protein in fractions
1–3 and 8–10. Soluble endoplasmic reticu-
lum (ER, BiP) and mitochondrial (PMPCB)
markers in fractions 1 and 2 reflect organ-
elle damage during fractionation.
(B) Western blot showing VPS13C immu-
noreactivity in mitochondria purified
by Percoll gradient centrifugation from
HEK293T cells (pM fraction). Note the
enrichment in VPS13C and the mitochon-
drial markers TOMM70 and PMPCB in the
pM fraction compared to the mitochon-
drion-enriched fraction (M). Abbreviation
is as follows: T, total lysate.
(C) Limited trypsin treatment of mito-
chondrion-enriched fractions (M) from
HEK293T or COS-7 cells caused loss of
VPS13C and the mitochondrial surface
marker TOMM70; the outer mitochondrial
membrane channel TOMM40 and the
matrix marker PMPCB are preserved.heterozygous truncating mutations in three PD-affected
individuals, absent from or present in the heterozygous
state in available unaffected family members and in a
very large number of control subjects, strongly support
the pathogenicity of VPS13C in EO parkinsonism. We
identified three affected individuals harboring VPS13C
mutations and could not perform co-segregation analyses,
due to the lack of additional affected relatives in the cor-
responding families. However, the affected individuals
shared a specific, rare, and extremely distinctive pheno-
type consisting of EO parkinsonism with very rapid
progression and dementia, which argues strongly for the
pathogenicity of VPS13C mutations. The initial pheno-
type, EO parkinsonism and a good response to levodopa
treatment, is similar to that of PD-affected individuals
with PARK2, PINK1, or DJ-1 mutations. However, the
affected individuals rapidly became bedridden because of
the worsening of motor dysfunction and loss of response
to treatment. Dysautonomia and pyramidal signs were
observed in two affected individuals, also distinguishing
the phenotype from the classical, slowly progressive EO
PD. The presence of numerous a-synuclein and ubiqui-
tin-positive-Lewy bodies in the brainstem, limbic system,
and many cortical areas was reminiscent of diffuse Lewy
body disease, consistent with a motor phenotype associ-
ated with dementia. a-synuclein Lewy bodies are absent
in most PD-affected individuals with PARK2 mutations,28
but were observed in the single autopsy case subject with
PINK1mutations reported.29 Tau-immunoreactive neurofi-
brillary tangles and neurites were also observed in case
subjects with PARK2 mutations.28 These features define
VPS13C-associated EO parkinsonism as a clinical, patho-
logical, and genetic entity belonging to the group of
synucleinopathies. In addition, our study also providesThe Ame31 potential candidate genes harboring disruptive homo-
zygous mutations in a single PD-affected individual. How-
ever, genetic replication and functional validation are still
needed to confirm their relevance to PD.
Alterations in other members of the VPS13 family cause
AR neurodegenerative disorders: VPS13A (MIM: 605978)
(CHAC [MIM: 200150]) is mutated in chorea-acanthocyto-
sis characterized by progressive neurodegeneration and red
cell acanthocytosis,30 and VPS13B (MIM: 607817) (COH1
[MIM: 216550]) is mutated in Cohen syndrome character-
ized by psychomotor retardation, microencephaly, and eye
abnormalities.31 VPS13A, VPS13B, and VPS13C are also
mutated in gastric and colorectal cancers with unstable
microsatellites.32
VPS13C belongs to a family of large VPS13 proteins
(VPS13A–D) similar to yeast Vps13p.23 Like yeast Vps,
mammalian vacuolar sorting proteins are crucial for
vesicular transport.33 Initial studies linked yeast VPS13
orthologs to the delivery of proteins to the vacuole,
the mammalian lysosome equivalent.34 Mutations in
VPS35, encoding a core component of the retromer
complex regulating endosomal protein sorting, are impli-
cated in AD late-onset PD.35,36 VPS35 is also involved
in protein trafficking from mitochondria to peroxi-
somes through mitochondria-derived vesicles.37 PINK1
and Parkin play a role in this transport route, which
delivers damaged mitochondrial cargo directly to lyso-
somes in response to mitochondrial stress.6 However,
the machinery regulating cargo selection and sorting
into vesicles remains to be identified. VPS13C might be
involved in this process. Such a mechanism would be
consistent with its mitochondrial localization and the
observed relocation to the cytosol in response to mito-
chondrial damage.rican Journal of Human Genetics 98, 500–513, March 3, 2016 507
Figure 4. VPS13C Silencing Impacts Mitochondrial Morphology, Transmembrane Potential, and Respiration
(A) Representative immunofluorescence staining illustrating mitochondrial perinuclear redistribution and fragmentation in COS-7 cells
silenced for VPS13C (siVPS13C, 30 nM) compared to cells treated with control siRNA (siControl, 30 nM): green, mitochondrial matrix
marker PMPCB; red, a-Tubulin. VPS13C silencing reduced VPS13C mRNA levels to no more than 25% of the control condition
(see Figure S6). Scale bars represent 10 mm. Quantification of aspect ratio and form factor (see Subjects and Methods, Koopman
et al.21, and Buhlman et al.22) shows reduced mitochondrial network complexity in siVPS13C-treated cells (means 5 SEM; **p <
0.01; ***p < 0.001, of n ¼ 88 or 86 cells scored per condition).
(B) Analysis of the relative TMRM fluorescence of mitochondria in COS-7 cells transfected as in (A), illustrating the decrease in DJmt in
cells depleted for VPS13C. n ¼ 40 cells per condition from one experiment representative of three carried out. ***p < 0.001.
(C) Oxygen consumption rates in intact COS-7 cells transfected with siControl or siVPS13C. The top panel shows the oxygen flux
corrected for instrumental background from one representative experiment. The graph in the bottom panel displays the respiration
rates. Absence of VPS13C is associated with increased maximal respiration (¼ maximal uncoupled respiration under CCCP  non-
mitochondrial respiration in the presence of the mitochondrial complex I and III inhibitors, rotenone, and antimycin A) and reserve
capacity (¼ maximal uncoupled respiration  basal respiration before the addition of the complex V inhibitor oligomycin). Means5
SEM; *p < 0.05, of six independent experiments.Several other observations in mammalian cells suggest
that, like PINK1 and Parkin, VPS13C plays a role in
mitochondrial maintenance. VPS13C depletion led to
reduction of DJmt and mitochondrial fragmentation in
cell lines. Moreover, it enhancedmaximal respiration rates,
suggesting compensatory adaptation aimed at preserving
DJmt levels. In neuronal cells, which produce ATP mainly
through mitochondrial oxidative phosphorylation and
are unable to switch to glycolysis under acute mitochon-
drial stress, such changes might in the long term exacer-
bate generation of reactive oxygen species and trigger
irreversible mitochondrial damage.38,39 VPS13C depletion
also upregulated PINK1/Parkin-dependent mitophagy,
and, similarly to PINK1 depletion, it enhanced the previ-508 The American Journal of Human Genetics 98, 500–513, March 3ously reported transcriptional upregulation of Parkin in
response to toxin-induced mitochondrial dysfunction.
Overall, these data suggest that loss of VPS13C function
increases mitochondrial vulnerability to stress and thereby
activates PINK1/Parkin-dependent mitochondrial quality
control pathways. Based on the inverse relationship be-
tween VPS13C and PINK1 protein levels on the mitochon-
drial surface, we cannot exclude that VPS13C also acts as a
negative regulator of PINK1.
Mitochondrial function is ensured by a series of intercon-
nected finely orchestrated pathways, activated in response
to different degrees of mitochondrial dysfunction.40 Exces-
sive mitophagy has been associated with a-synuclein-
dependent neurodegeneration.41 Further work is required, 2016
Figure 5. Loss of VPS13C Function Enhances Mitochondrial Accumulation of PINK1, Recruitment of Parkin, and PARK2 Upregulation
in Response to CCCP
(A and B)Western blot (A) and corresponding VPS13C protein levels (B) (normalized to a-Tubulin or PMPCB) in cytosolic (C), mitochon-
drion-enriched (M), and total (T) cell fractions from HEK293T cells treated or not with CCCP (10 mM, 3 hr). VPS13C levels decreased
significantly in mitochondria after CCCP treatment, but tended to increase in cytosol (means 5 SEM; *p < 0.05, of six independent
fractionation experiments).
(C–E) Western blot (C) and corresponding normalized protein levels (D, E) in cytosolic and mitochondrion-enriched fractions from
HEK293T transfected with 30 nM of control siRNA (siControl) or siRNA targeting VPS13C (siVPS13C).
(D) CCCP treatment resulted in accumulation of PINK1 (endogenous) in mitochondrion-enriched fractions (M) after treatment with
siControl () and, more significantly, with siVPS13C (þ).
(E) Accumulation of Parkin (endogenous) on depolarized mitochondria was also strongly enhanced in cells treated with siVPS13C. In
addition, Parkin levels were upregulated in the cytosolic (C) fractions, particularly in untreated cells (means 5 SEM; *p < 0.05 of
four independent fractionation experiments).
(F) Quantitative real-time RT-PCR showing relative mRNA levels, normalized to a-actin (ACTB), in HEK293T cells treated with control
siRNA (siControl), or siRNA targeting VPS13C (siVPS13C) or PINK1 (siPINK1), under basal conditions or after CCCP treatment. Note
the more than 30% decrease in VPS13C mRNA levels after PINK1 silencing under basal conditions, but not after CCCP treatment
(left). Note also that VPS13C and PINK1 silencing enhance the upregulation of PARK2 mRNA at 48 hr of CCCP treatment (right);
means 5 SEM of three to nine replicates per condition from two independent experiments (**p < 0.01; ***p < 0.001 compared to
siControl within each condition of CCCP treatment; ###p < 0.001 between the indicated conditions of CCCP treatments).to clarify the role of VPS13C inmitochondrialmaintenance
and dissect its possible relation to PINK1/Parkin-dependent
pathways.
Enrichment of VPS13C in cell fractions containing the
early endosomal marker EEA1 suggests broader roles forThe AmeVPS13C invesicular trafficking.Amoregeneral involvement
in endosomal-lysosomal trafficking, possibly counteracting
a-synuclein pathology as recently reported for VPS35,42
might explain the diffuse a-synuclein pathology and
rapid progression to dementia in individuals with VPS13Crican Journal of Human Genetics 98, 500–513, March 3, 2016 509
Figure 6. Loss of VPS13C Function Exacerbates PINK1/Parkin-Dependent Mitophagy
(A) Immunofluorescence staining of a representative experiment illustrating PINK1/Parkin-dependent mitophagy in COS-7 cells
overproducing Parkin and silenced for VPS13C or PINK1 (20 nM siRNA) after CCCP treatment (10 mM for 48 hr): red, Parkin; green,
mitochondrial matrix marker PMPCB. Open arrows indicate loss of mitochondrial networks; white arrows show preserved networks.
Scale bars represent 10 mm.
(B) Quantification of mitophagy in the conditions described in (A), expressed as the proportion of COS-7 cells without PMPCB (black
bars) or TOMM20 (gray bars) staining; the siVPS13C treatment increased and siPINK1 decreased the proportion. In the absence of exog-
enous Parkin (Parkin; cells overproducing the control protein EGFP) or CCCP (not shown), all the cells harbored normalmitochondrial
PMPCB staining, whether or not VPS13C was silenced (means 5 SEM; *p < 0.05, **p < 0.01 of 3 independent experiments; 100 cells
scored per condition).
(C) Proportion of COS-7 cells without PMPCB staining after transfection with half-doses (10 nM) of each siRNA and 48 hr of CCCP treat-
ment. Themitophagy-promoting effect ofVPS13C depletion was abolished by concomitant silencing of PINK1 (means5 SEM; *p< 0.05
of 3 independent experiments; 100 cells scored per condition).mutations. Such a mechanism would potentially represent
a unifying link with cellular pathways involved in AD PD.
In summary, we describe truncating mutations in
VPS13C associated with EO parkinsonism with rapid
progression and widely distributed Lewy bodies. A meta-
analysis of PD genome-wide association studies recently
identified a susceptibility allele ~250 kb from VPS13C but
not associated with either CpG methylation or mRNA
expression,43 suggesting that VPS13C can either cause a
monogenic form of EO parkinsonism or confer genetic
susceptibility to PD. Although we are confident that our
work strongly implicates VPS13Cmutations in PD, further
genetic studies in other populations are needed to confirm
their pathogenicity. The development of animal models in
which VPS13C is stably inactivated will help dissect the
mechanisms by which loss of VPS13C function affects
the survival of dopaminergic neurons.Accession Numbers
The accession numbers for the variations inVPS13C reported in this
paper areClinVar: SCV000262816,SCV000262817, SCV000262818,
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